Insiders who reported open-market trades in the last 12 months at the companies Michael A. Metzger files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Michael A. Metzger is a corporate insider, tracked as Chief Executive Officer of Syndax Pharmaceuticals Inc (SNDX). InsiderAlpha holds 7 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Michael A. Metzger last file a Form 4?
The most recent primary Form 4 on record is dated 9 July 2026, one of 7 filings going back to 2025.
Has Michael A. Metzger been buying or selling stock?
Recorded transactions: 0 open-market purchases and 6 open-market sales ($4.08M) across all tracked filings.
Michael A. Metzger is Chief Executive Officer of Syndax Pharmaceuticals Inc (SNDX). 7 SEC Form 4 filings on record going back to 2025, most recently on 9 July 2026. Most recent open-market trade: sold $785K of SNDX on 9 July 2026. Lifetime open-market sales: $4.08M.
Recent transactions
10
The latest 10 SEC Form 4 transactions reported by Michael A. Metzger.
InsiderAlpha's records for Michael A. Metzger go back to 2025: 7 primary Form 4 filings, an average of 3.5 per year. 3 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
